文献速递乳房整形与再造显微修复重建

DIEP皮瓣乳房再造围手术期CDK4/6抑制剂早期安全性数据与管理策略

Peri-operative CDK4/6 inhibitors in DIEP flap breast reconstruction: Early safety data and proposed management strategy.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-08-06

本文首次报告围手术期接受CDK4/6抑制剂患者行单侧DIEP皮瓣乳房再造的术后结局:232例中9例(4%)暴露于CDK4/6抑制剂,暴露组无轻微及重大并发症,非暴露组分别为11%和2.2%,差异无统计学意义。作者建议与肿瘤科密切协调临时停药,并呼吁更大规模多中心研究评估风险。

要点

  • 围手术期CDK4/6抑制剂暴露未增加DIEP皮瓣再造术后并发症。
  • 暴露组术前血红蛋白、白细胞、中性粒细胞及淋巴细胞计数均显著降低。
  • 建议与肿瘤科协调术前临时停药,中位停药2周。

核心结论

  • 早期系列显示围手术期CDK4/6抑制未对DIEP皮瓣乳房再造的手术结局产生不良影响。

研究设计与样本

  • 回顾性连续队列系列,纳入2024年1月至2026年1月本机构所有单侧DIEP乳房再造患者232例,其中9例(4%)接受围手术期CDK4/6抑制剂。

主要发现

  • CDK4/6抑制剂组轻微并发症发生率为0%,非暴露组为11%(p=0.6)。
  • CDK4/6抑制剂组重大并发症发生率为0%,非暴露组为2.2%(p=1.0)。
  • CDK4/6抑制剂组术前血红蛋白、白细胞、中性粒细胞及淋巴细胞计数均显著低于非暴露组(p<0.05)。
  • 使用的CDK4/6抑制剂包括Abemaciclib(n=6)、Ribociclib(n=2)和Palbociclib(n=1)。
  • 患者被建议术前中位停药2周。

关键数值与推荐

  • CDK4/6抑制剂组术前中位停药2周。

临床怎么用

  • 围手术期使用CDK4/6抑制剂患者可考虑行DIEP皮瓣乳房再造,但需与肿瘤科密切协调临时停药。

局限性

  • 样本量小(CDK4/6抑制剂组仅9例),需更大规模多中心研究全面评估围手术期CDK4/6抑制剂在自体再造中的风险特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has significantly altered the treatment paradigm for hormone receptor-positive, HER2-negative breast cancer. Increasingly, surgeons encounter patients receiving these agents at the time of breast reconstruction, yet there is no published evidence on the safety of free tissue transfer in this context. We present the first series examining post-operative outcomes in patients exposed to CDK4/6 inhibitors undergoing deep inferior epigastric perforator (DIEP) flap breast reconstruction and outline a pragmatic management approach. We report a retrospective, consecutive cohort series of all unilateral DIEP breast reconstructions undertaken between January 2024 and January 2026 at our institution. We include 232 patients, 9 of whom (4%) underwent peri-operative CDK4/6 inhibition. The median age was 51 years. Overall, 18% of patients were obese (BMI ≥ 30), 7% had a smoking history, and 2% had diabetes. CDK4/6 inhibitors administered were Abemaciclib (n=6), Ribociclib (n=2) and Palbociclib (n=1), and patients were recommended a median of 2 weeks off treatment pre-operatively. Pre-operative haemoglobin, white cell, neutrophil and lymphocyte counts were all significantly lower in the CDK4/6 inhibitor group (p<0.05). No minor complications occurred in CDK4/6 patients compared with 11% in non-exposed patients (p=0.6). Major complications were rare, occurring in 0% of CDK4/6 inhibitor patients and 2.2% of non-exposed patients (p=1.0). In this early series, CDK4/6 inhibition did not adversely affect surgical outcomes. We advocate for close coordination with oncology regarding temporary treatment interruption. Larger, multi-centre studies are needed to fully assess the risk profile of peri-operative CDK4/6 inhibitors in autologous reconstruction.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Sharp O, Yousif Y, Battisti NML, et al. Peri-operative CDK4/6 inhibitors in DIEP flap breast reconstruction: Early safety data and proposed management strategy. J Plast Reconstr Aesthet Surg. 2026. PMID: 42600543. doi:10.1016/j.bjps.2026.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。